Page last updated: 2024-11-12

pf 03491390

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID12000240
CHEMBL ID197672
SCHEMBL ID3288801
MeSH IDM0516655

Synonyms (50)

Synonym
HY-10396
pf-03491390
idn-6556
idn 6556
emricasan
pf 03491390
vay-785
vay785
CHEMBL197672
(s)-3-((s)-2-(2-(2-tert-butylphenylamino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
(3s)-3-(n2-((2-tert-butylphenyl)oxamoyl)-l-alaninamido)-4-oxo-5-(2,3,5,6- tetrafluorophenoxy)pentanoic acid
unii-p0gms9n47q
l-alaninamide, n-(2-(1,1-dimethylethyl)phenyl)-2-oxoglycyl-n-((1s)-1-(carboxymethyl)-2-oxo-3-(2,3,5,6-tetrafluorophenoxy)propyl)-
emricasan [usan:inn]
p0gms9n47q ,
emricasan (usan/inn)
D10004
254750-02-2
AKOS016009462
NCGC00346477-01
CS-0599
S7775
(3s)-3-[[(2s)-2-[[2-[(2-tert-butylphenyl)amino]-2-oxoacetyl]amino]propanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
gtpl6508
emricasan [inn]
(3s)-3-((2s)-2-((n-(2-tert-butyl)phenyl)carbamoyl)carbonylamino) propanoylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
(3s)-3-(n2-((2-tert-butylphenyl)oxamoyl)-l-alaninamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
emricasan [usan]
emricasan [who-dd]
SCHEMBL3288801
AC-31507
c26h27f4n3o7
(s)-3-((s)-2-(2-((2-(tert-butyl)phenyl)amino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
DTXSID10180160
(3s)-3-[(2s)-2-{[(2-tert-butylphenyl)carbamoyl]formamido}propanamido]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
AS-75073
DB05408
pf03491390
BCP07463
emricasan (idn-6556, pf-03491390)
EX-A1659
Q27077178
emricasan(idn6556,pf03491390)
(3s)-3-[[(2s)-2-[[2-(2-tert-butylanilino)-2-oxoacetyl]amino]propanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
AMY36447
CCG-270089
bdbm50461533
A857136
(s)-3-((s)-2-(2-((2-(tert-butyl)phenyl)amino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoicacid
emricasan(idn6556)

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency13.13730.00529.466132.9993AID1347411
Interferon betaHomo sapiens (human)Potency13.13730.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Caspase-3Homo sapiens (human)IC50 (µMol)0.00600.00021.19798.8000AID1391986
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (86)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
neurotrophin TRK receptor signaling pathwayCaspase-3Homo sapiens (human)
luteolysisCaspase-3Homo sapiens (human)
response to hypoxiaCaspase-3Homo sapiens (human)
B cell homeostasisCaspase-3Homo sapiens (human)
negative regulation of cytokine productionCaspase-3Homo sapiens (human)
proteolysisCaspase-3Homo sapiens (human)
apoptotic processCaspase-3Homo sapiens (human)
DNA damage responseCaspase-3Homo sapiens (human)
axonal fasciculationCaspase-3Homo sapiens (human)
heart developmentCaspase-3Homo sapiens (human)
sensory perception of soundCaspase-3Homo sapiens (human)
learning or memoryCaspase-3Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to osmotic stressCaspase-3Homo sapiens (human)
response to xenobiotic stimulusCaspase-3Homo sapiens (human)
response to UVCaspase-3Homo sapiens (human)
response to woundingCaspase-3Homo sapiens (human)
response to glucoseCaspase-3Homo sapiens (human)
response to X-rayCaspase-3Homo sapiens (human)
regulation of macroautophagyCaspase-3Homo sapiens (human)
protein processingCaspase-3Homo sapiens (human)
hippocampus developmentCaspase-3Homo sapiens (human)
protein catabolic processCaspase-3Homo sapiens (human)
erythrocyte differentiationCaspase-3Homo sapiens (human)
platelet formationCaspase-3Homo sapiens (human)
negative regulation of B cell proliferationCaspase-3Homo sapiens (human)
regulation of protein stabilityCaspase-3Homo sapiens (human)
response to cobalt ionCaspase-3Homo sapiens (human)
response to estradiolCaspase-3Homo sapiens (human)
response to lipopolysaccharideCaspase-3Homo sapiens (human)
glial cell apoptotic processCaspase-3Homo sapiens (human)
response to tumor necrosis factorCaspase-3Homo sapiens (human)
response to nicotineCaspase-3Homo sapiens (human)
response to hydrogen peroxideCaspase-3Homo sapiens (human)
T cell homeostasisCaspase-3Homo sapiens (human)
response to amino acidCaspase-3Homo sapiens (human)
fibroblast apoptotic processCaspase-3Homo sapiens (human)
cell fate commitmentCaspase-3Homo sapiens (human)
negative regulation of cell cycleCaspase-3Homo sapiens (human)
negative regulation of activated T cell proliferationCaspase-3Homo sapiens (human)
striated muscle cell differentiationCaspase-3Homo sapiens (human)
response to glucocorticoidCaspase-3Homo sapiens (human)
neuron apoptotic processCaspase-3Homo sapiens (human)
protein maturationCaspase-3Homo sapiens (human)
anterior neural tube closureCaspase-3Homo sapiens (human)
pyroptosisCaspase-3Homo sapiens (human)
leukocyte apoptotic processCaspase-3Homo sapiens (human)
cellular response to staurosporineCaspase-3Homo sapiens (human)
apoptotic signaling pathwayCaspase-3Homo sapiens (human)
intrinsic apoptotic signaling pathwayCaspase-3Homo sapiens (human)
execution phase of apoptosisCaspase-3Homo sapiens (human)
positive regulation of pyroptosisCaspase-3Homo sapiens (human)
positive regulation of amyloid-beta formationCaspase-3Homo sapiens (human)
epithelial cell apoptotic processCaspase-3Homo sapiens (human)
keratinocyte differentiationCaspase-3Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-3Homo sapiens (human)
neuron differentiationCaspase-3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
protease bindingCaspase-3Homo sapiens (human)
aspartic-type endopeptidase activityCaspase-3Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-3Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase inhibitor activityCaspase-3Homo sapiens (human)
death receptor bindingCaspase-3Homo sapiens (human)
protein bindingCaspase-3Homo sapiens (human)
peptidase activityCaspase-3Homo sapiens (human)
phospholipase A2 activator activityCaspase-3Homo sapiens (human)
protein-containing complex bindingCaspase-3Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-3Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic signaling pathwayCaspase-3Homo sapiens (human)
cysteine-type endopeptidase activity involved in execution phase of apoptosisCaspase-3Homo sapiens (human)
enzyme activator activityCaspase-3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
nucleusCaspase-3Homo sapiens (human)
cytoplasmCaspase-3Homo sapiens (human)
nucleusCaspase-3Homo sapiens (human)
nucleoplasmCaspase-3Homo sapiens (human)
cytosolCaspase-3Homo sapiens (human)
neuronal cell bodyCaspase-3Homo sapiens (human)
death-inducing signaling complexCaspase-3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (66)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347155Optimization screen NINDS Rhodamine qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347158ZIKV-mCherry secondary qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347150Optimization screen NINDS AMC qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347156DAPI mCherry counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347164384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1391992Clearance in C57BL/6J mouse at 1 mg/kg, iv after 0.25 to 24 hrs by LC-MS/MS method2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
Structure-activity relationship study of a series of caspase inhibitors containing γ-amino acid moiety for treatment of cholestatic liver disease.
AID1391986Inhibition of Anti-Fas antibody-induced caspase-3 activity in human Jurkat E6-1 cells using Ac-DEVD-AMC substrate by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
Structure-activity relationship study of a series of caspase inhibitors containing γ-amino acid moiety for treatment of cholestatic liver disease.
AID1391994AUC (0 to infinity) in C57BL/6J mouse at 1 mg/kg, iv after 0.25 to 24 hrs by LC-MS/MS method2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
Structure-activity relationship study of a series of caspase inhibitors containing γ-amino acid moiety for treatment of cholestatic liver disease.
AID1391991Volume of distribution at steady state in C57BL/6J mouse at 1 mg/kg, iv after 0.25 to 24 hrs by LC-MS/MS method2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
Structure-activity relationship study of a series of caspase inhibitors containing γ-amino acid moiety for treatment of cholestatic liver disease.
AID255191Inhibitory activity against Caspase-32005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
First-in-class pan caspase inhibitor developed for the treatment of liver disease.
AID638177Permeability from basal to apical side across human Caco2 cells2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Synthesis and evaluation of novel prodrugs of caspase inhibitors.
AID255194Inhibitory activity against murine Caspase-12005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
First-in-class pan caspase inhibitor developed for the treatment of liver disease.
AID1391995AUC (0 to infinity) in C57BL/6J mouse at 10 mg/kg, po after 0.25 to 24 hrs by LC-MS/MS method2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
Structure-activity relationship study of a series of caspase inhibitors containing γ-amino acid moiety for treatment of cholestatic liver disease.
AID1391989AUC in C57BL/6J mouse liver at 1 mg/kg, po after 0.5 to 6 hrs by LC-MS/MS method2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
Structure-activity relationship study of a series of caspase inhibitors containing γ-amino acid moiety for treatment of cholestatic liver disease.
AID255771Inhibitory concentration against THP-1 cells2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
First-in-class pan caspase inhibitor developed for the treatment of liver disease.
AID1391996Oral bioavailability in C57BL/6J mouse at 10 mg/kg after 0.25 to 24 hrs by LC-MS/MS method2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
Structure-activity relationship study of a series of caspase inhibitors containing γ-amino acid moiety for treatment of cholestatic liver disease.
AID1391993Half life in C57BL/6J mouse at 1 mg/kg, iv after 0.25 to 24 hrs by LC-MS/MS method2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
Structure-activity relationship study of a series of caspase inhibitors containing γ-amino acid moiety for treatment of cholestatic liver disease.
AID638176Permeability from apical to basal side across human Caco2 cells2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Synthesis and evaluation of novel prodrugs of caspase inhibitors.
AID255192Inhibitory activity against Caspase-62005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
First-in-class pan caspase inhibitor developed for the treatment of liver disease.
AID255193Inhibitory activity against Caspase-82005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
First-in-class pan caspase inhibitor developed for the treatment of liver disease.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID255770Inhibitory concentration against JFas cells2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
First-in-class pan caspase inhibitor developed for the treatment of liver disease.
AID1391990Cmax in C57BL/6J mouse at 10 mg/kg, po after 0.25 to 24 hrs by LC-MS/MS method2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
Structure-activity relationship study of a series of caspase inhibitors containing γ-amino acid moiety for treatment of cholestatic liver disease.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID255698Effective dose required for pancaspase inhibition in a-Fas liver upon i.p. administration; range = 0.06-0.122005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
First-in-class pan caspase inhibitor developed for the treatment of liver disease.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1345414Human Caspase 8 (C14: Caspase)2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
First-in-class pan caspase inhibitor developed for the treatment of liver disease.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (7.69)29.6817
2010's5 (38.46)24.3611
2020's7 (53.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.67 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index5.12 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]